Detalhe da pesquisa
1.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Gastroenterology
; 164(1): 72-88.e18, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108710
2.
CXCR2 inhibition enables NASH-HCC immunotherapy.
Gut
; 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477863
3.
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
J Hepatol
; 75(4): 865-878, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33992698
4.
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Gastroenterology
; 157(5): 1383-1397.e11, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31344396
5.
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials.
Br J Cancer
; 121(4): 340-343, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285588
6.
Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
J Hepatol
; 75(6): 1515, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627652
7.
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Mol Cancer Ther
; 22(4): 485-498, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780225